PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK ‐rearranged lung cancer

Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non‐small‐cell lung cancer (NSCLC) patients with ALK‐rearranged tumors. However, clinical resistance typically develops over time and, in the majority of cases, resistance mechanisms are ALK‐independent. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Talwelkar, Sarang S., Mäyränpää, Mikko I., Schüler, Julia, Linnavirta, Nora, Hemmes, Annabrita, Adinolfi, Simone, Kankainen, Matti, Sommergruber, Wolfgang, Levonen, Anna‐Liisa, Räsänen, Jari, Knuuttila, Aija, Verschuren, Emmy W., Wennerberg, Krister
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158778/
https://www.ncbi.nlm.nih.gov/pubmed/36423211
http://dx.doi.org/10.1002/1878-0261.13342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158778/
https://www.ncbi.nlm.nih.gov/pubmed/36423211
http://dx.doi.org/10.1002/1878-0261.13342

Ejemplares similares